NL9102122A - Werkwijze voor het testen van antivirale middelen; daarvoor bruikbare proefdieren. - Google Patents
Werkwijze voor het testen van antivirale middelen; daarvoor bruikbare proefdieren. Download PDFInfo
- Publication number
- NL9102122A NL9102122A NL9102122A NL9102122A NL9102122A NL 9102122 A NL9102122 A NL 9102122A NL 9102122 A NL9102122 A NL 9102122A NL 9102122 A NL9102122 A NL 9102122A NL 9102122 A NL9102122 A NL 9102122A
- Authority
- NL
- Netherlands
- Prior art keywords
- cells
- immune system
- animals
- mice
- administered
- Prior art date
Links
- 241001465754 Metazoa Species 0.000 title claims description 47
- 238000012360 testing method Methods 0.000 title claims description 47
- 238000000034 method Methods 0.000 title claims description 30
- 239000003443 antiviral agent Substances 0.000 title claims description 10
- 229940121357 antivirals Drugs 0.000 title description 3
- 241000700605 Viruses Species 0.000 claims description 42
- 241000699670 Mus sp. Species 0.000 claims description 39
- 210000004027 cell Anatomy 0.000 claims description 39
- 210000000987 immune system Anatomy 0.000 claims description 38
- 230000001506 immunosuppresive effect Effects 0.000 claims description 27
- 238000010171 animal model Methods 0.000 claims description 17
- 210000004698 lymphocyte Anatomy 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 230000005855 radiation Effects 0.000 claims description 12
- 208000024908 graft versus host disease Diseases 0.000 claims description 11
- 210000002798 bone marrow cell Anatomy 0.000 claims description 8
- 238000002054 transplantation Methods 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 6
- 241000894007 species Species 0.000 claims description 6
- 230000035772 mutation Effects 0.000 claims description 5
- 239000000824 cytostatic agent Substances 0.000 claims description 4
- 230000001085 cytostatic effect Effects 0.000 claims description 4
- 230000001771 impaired effect Effects 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 4
- 241000700198 Cavia Species 0.000 claims description 3
- 241000699800 Cricetinae Species 0.000 claims description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 3
- 241000700159 Rattus Species 0.000 claims description 3
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 8
- 208000009329 Graft vs Host Disease Diseases 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 210000001185 bone marrow Anatomy 0.000 description 6
- 208000030507 AIDS Diseases 0.000 description 5
- 210000000683 abdominal cavity Anatomy 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 210000005260 human cell Anatomy 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000012531 culture fluid Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 3
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 3
- 241000282560 Macaca mulatta Species 0.000 description 3
- 241000714177 Murine leukemia virus Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 241000282579 Pan Species 0.000 description 3
- 238000011579 SCID mouse model Methods 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 241000251204 Chimaeridae Species 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 230000003319 supportive effect Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 2
- 229960002555 zidovudine Drugs 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000001494 anti-thymocyte effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- TVFDJXOCXUVLDH-RNFDNDRNSA-N cesium-137 Chemical compound [137Cs] TVFDJXOCXUVLDH-RNFDNDRNSA-N 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 208000003669 immune deficiency disease Diseases 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 108010043277 recombinant soluble CD4 Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/02—Breeding vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
- G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
- G01N2333/16—HIV-1, HIV-2
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Environmental Sciences (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL9102122A NL9102122A (nl) | 1991-12-18 | 1991-12-18 | Werkwijze voor het testen van antivirale middelen; daarvoor bruikbare proefdieren. |
| PCT/NL1992/000226 WO1993012252A1 (fr) | 1991-12-18 | 1992-12-15 | Procede de mise a l'epreuve d'agents antiviraux et animaux d'experience utilises dans ce procede |
| AU32686/93A AU3268693A (en) | 1991-12-18 | 1992-12-15 | Method for testing antiviral agents; experimental animals useful therefor |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL9102122 | 1991-12-18 | ||
| NL9102122A NL9102122A (nl) | 1991-12-18 | 1991-12-18 | Werkwijze voor het testen van antivirale middelen; daarvoor bruikbare proefdieren. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL9102122A true NL9102122A (nl) | 1993-07-16 |
Family
ID=19860055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL9102122A NL9102122A (nl) | 1991-12-18 | 1991-12-18 | Werkwijze voor het testen van antivirale middelen; daarvoor bruikbare proefdieren. |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU3268693A (fr) |
| NL (1) | NL9102122A (fr) |
| WO (1) | WO1993012252A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994005779A1 (fr) * | 1992-09-09 | 1994-03-17 | O'brien, Caroline, Jane | Procede de verification de reponse immune individuelle a un anticorps a l'aide d'une souris a scid |
| NL9400157A (nl) * | 1994-02-02 | 1995-09-01 | Smit Victor | Werkwijze voor de produktie van virussen en virus resistente cellen en het testen van antivirale middelen met gebruik van proefdieren. |
| NL9400156A (nl) * | 1994-02-02 | 1995-09-01 | Smit Victor | Werkwijze voor het produceren van immunologische produkten en/of cellen en het testen van immuun modulerende substanties, met gebruik van proefdieren. |
| FR2729973B1 (fr) * | 1995-01-26 | 1997-04-04 | Centre Nat Rech Scient | Procede de criblage de composes anti-viraux |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2071620T3 (es) * | 1987-12-23 | 1995-07-01 | Univ Leland Stanford Junior | Mamiferos inmunodeficientes quimericos y su utilizacion. |
| US5183949A (en) * | 1988-09-22 | 1993-02-02 | The United States Of America As Represented By The Department Of Health And Human Services | Rabbit model for diagnosing and testing vaccines or therapeutic agents against aids |
-
1991
- 1991-12-18 NL NL9102122A patent/NL9102122A/nl not_active Application Discontinuation
-
1992
- 1992-12-15 WO PCT/NL1992/000226 patent/WO1993012252A1/fr active Application Filing
- 1992-12-15 AU AU32686/93A patent/AU3268693A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU3268693A (en) | 1993-07-19 |
| WO1993012252A1 (fr) | 1993-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Boia et al. | Neuroprotective strategies for retinal ganglion cell degeneration: current status and challenges ahead | |
| Laidlaw | Virus diseases and viruses | |
| JP2981486B2 (ja) | 哺乳動物の免疫系研究方法 | |
| Berg et al. | Propagation of Measles Virus in Suspensions of Human and Monkey Leucocytes. | |
| Guzman et al. | Contributions of farm animals to immunology | |
| Chirigos | Studies with the Murine Leukemogenic Rauscher Virus: III. An in Vivo Assay for Anti-Viral Agents | |
| KR20130033354A (ko) | Ｎｋ세포 강화형 혈액제제의 제조 방법 | |
| US20180117134A1 (en) | Therapeutic vaccine for treatment of diabetes type 1 in children, application of the cell sorter and the method of multiplying treg cells to produce therapeutic vaccine for treatment of diabetes type 1 | |
| Kilham et al. | Transplacental infection of rats and hamsters induced by oral and parenteral inoculations of H‐1 and rat viruses (RV) | |
| JP2001149069A (ja) | ナチュラルキラー細胞の増殖方法 | |
| Kobayashi et al. | Retinoblastoma-like tumors induced by human adenovirus type 12 in rats | |
| NL9102122A (nl) | Werkwijze voor het testen van antivirale middelen; daarvoor bruikbare proefdieren. | |
| WO1999012032A1 (fr) | Procede d'evaluation de medicaments antiviraux | |
| Meeker et al. | Microglial proliferation in cortical neural cultures exposed to feline immunodeficiency virus | |
| JP2018162974A (ja) | 造血器腫瘍治療剤、およびスクリーニング方法 | |
| Danner et al. | Implantation of cultured thymic fragments in patients with acquired immunodeficiency syndrome | |
| DE69429657T2 (de) | Verwendung von modifizierten tall-104 zellen zur behandlung von krebs und viralen krankheiten | |
| Randall et al. | Detection by Tissue Culture of an Organism Resembling Histoplasma capsulation in an Apparently Healthy Horse. | |
| Hays et al. | Stimulation of in-vitro growth of rat liver cells with calf serum drawn following partial hepatectomy | |
| SUTTON et al. | Drug effects on survival of homografts of skins | |
| Rafferty Jr | The physiology of amphibian cells in culture | |
| COTLIER | Rubella in animals and experimental ocular aspects of congenital rubella | |
| Panigrahi et al. | Xenotransplantation: an insight | |
| Forger III et al. | Thymic hormone modulation of leukemogenic virus replication | |
| RU2339700C1 (ru) | Способ постановки биологической пробы для определения видовой принадлежности микобактерий |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1B | A search report has been drawn up | ||
| BV | The patent application has lapsed |